![]() |
![]() |
Legal status
Patent not validated
(51) | INT.CL. | A61K 38/48 | |
A61P 7/04 |
(11) | Number of the document | 1761274 |
(13) | Kind of document | T |
(96) | European patent application number | 05756838.8 |
Date of filing the European patent application | 2005-06-21 | |
(97) | Date of publication of the European application | 2007-03-14 |
(45) | Date of publication and mention of the grant of the patent | 2009-09-02 |
(46) | Date of publication of the claims translation |
(86) | Number | PCT/EP2005/052890 |
Date | 2005-06-21 |
(87) | Number | WO 2005/123118 |
Date | 2005-12-29 |
(30) | Number | Date | Country code |
200400972 | 2004-06-21 | DK | |
200400981 | 2004-06-23 | DK |
(72) |
BRUN, Nikolai Constantin, DK
ERHARDTSEN, Elisabeth, DK
SKOLNICK, Brett E., US
|
(73) |
Novo Nordisk Health Care AG,
Andreasstrasse 15, 8050 Zürich,
CH
|
(54) | FACTOR VIIA OR FACTOR VIIA EQUIVALENTS FOR PREVENTING OR ATTENTUATING HAEMORRHAGE GROWTH, AND/OR OEDEMA GENERATION FOLLOWING INTRACEREBRAL HAEMORRHAGE (ICH) |
FACTOR VIIA OR FACTOR VIIA EQUIVALENTS FOR PREVENTING OR ATTENTUATING HAEMORRHAGE GROWTH, AND/OR OEDEMA GENERATION FOLLOWING INTRACEREBRAL HAEMORRHAGE (ICH) |